ARCHIVES

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

Solomon Gard’s Questions/Answers

January 2, 1981

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

$20 Million In Construction Funds Approved

April 2, 1976

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

Congressional Committees Add Provisions To Cancer Act Renewal Bills To Strengthen NCI’s Independence, Prevent Fund Withholding

March 8, 1974

Final Issue of the Year

December 13, 1985